Companies ›Healthcare ›KRYS.O

KRYS.O — NASDAQ Diversified Pharmaceuticals

Krys.O

$312,57

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

9,2B USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

41,5 %

ROE

16,8 %

Net margin

52,6 %

Debt / equity

0,00

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$366,85

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

KRYSTAL Biotech is a biopharmaceutical company focused on the development and commercialization of therapies for dermatological and autoimmune diseases, primarily through its lead product, Krystexxa, for the treatment of chronic gout.

Business. KRYS.O is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY12 analysts

11 buy1 hold0 sell

Avg 12m price target364,53

Analyst recommendations

12 analysts · consensus Buy

Buy11

Hold1

Sell0

12-month price target

364,53

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

12 analysts · indicative

Ownership→

iShares Core S&P Small-Cap ETF

largest disclosed fund holder

Profitability→

16,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning KRYS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to KRYS.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

KRYS.O is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the broader Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

AI synthesis

GENERATED

KRYSTAL Biotech maintains a strong liquidity position, with a current ratio of 9.95 and $496.3 million in cash and equivalents, indicating a robust ability to meet short-term obligations. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure. The price-to-book ratio of 8.79 and price-to-tangible-book ratio of 8.79 reflect a premium valuation relative to its book value.

In terms of profitability, KRYSTAL Biotech reported a net income of $204.8 million and an operating income of $161.3 million, with a return on equity of 16.8% and a return on assets of 15.36%. These figures are well above the industry median for profitability metrics, indicating strong operational efficiency and effective use of capital.

The company's revenue is concentrated in a single therapeutic area, primarily driven by Krystexxa, with no disclosed geographic diversification in the financial data. This concentration may expose the company to risks associated with regulatory changes, product competition, or shifts in market demand for gout treatments.

KRYSTAL Biotech's revenue growth trajectory is not explicitly provided in the financial data, but the company's high price-to-earnings ratio of 52.33 and price-to-revenue ratio of 26.27 suggest that the market is pricing in future growth expectations. Analysts have assigned a mean price target of $314.70, with a median of $316.50, indicating a generally positive outlook despite the high valuation.

The risk assessment for KRYSTAL Biotech indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company has not issued additional shares recently, and its diluted share count is equal to its basic share count, suggesting no near-term dilution pressure. The absence of long-term debt also reduces financial risk.

Recent events include the continued commercialization of Krystexxa, with no major regulatory or legal challenges reported in the latest filings. The company's focus on dermatological and autoimmune diseases remains unchanged, and there are no indications of significant strategic shifts in the near term.

Key takeaways

KRYSTAL Biotech has a strong liquidity position with $496.3 million in cash and equivalents and no long-term debt.
The company's profitability metrics, including a 16.8% return on equity, are well above industry medians.
Revenue is concentrated in a single therapeutic area, primarily driven by Krystexxa, with no geographic diversification disclosed.
Analysts have a generally positive outlook, with a mean price target of $314.70, despite a high price-to-earnings ratio of 52.33.
The company faces low liquidity and dilution risks, with no immediate filing-based flags detected.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$312,57

Market cap

$10.72B

Enterprise valueⓘ

$10.22B

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

50.9x

P / Bⓘ

8.8x

P / Tangible bookⓘ

8.8x

Tangible book

$1.22B

Net cashⓘ

$496.3M

Current ratioⓘ

9.9

Debt / equityⓘ

0.0

ROAⓘ

15.4%

ROEⓘ

16.8%

Cash conversionⓘ

98.0%

CapEx / revenueⓘ

-3.1%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs KRYS · multiples and returns

MCK—

Mckesson Corp

$827,14

102,6B USD

P/E

21,2x

-24,6 vs self

Div yield

0,4 %

— vs self

ROE

-219,2 %

-235,3 vs self

COR—

Cencora Inc

$308,37

60,2B USD

P/E

36,4x

-9,5 vs self

Div yield

0,8 %

— vs self

ROE

45,7 %

+29,7 vs self

CAH—

Cardinal Health Inc

$235,60

57,0B USD

P/E

36,7x

-9,2 vs self

Div yield

0,9 %

— vs self

ROE

-55,9 %

-72,0 vs self

DB—

DB.V

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

REGN—

REGENERON PHARMACEUTICALS, INC.

$757,99

81,0B USD

P/E

15,5x

-30,4 vs self

Div yield

—

— vs self

ROE

14,2 %

-1,8 vs self

BIIB—

BIOGEN INC.

$201,74

29,6B USD

P/E

21,3x

-24,6 vs self

Div yield

—

— vs self

ROE

7,5 %

-8,5 vs self

ZTS—

Zoetis Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

GRFS—

Grifols SA

$7,86

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 43 %

EPS

Consensus EPS

7,36

Predicted surprise

-0,05

Beat probability

43 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

revision ratio -0,04 · as of 2026-08-02 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	7,36
Revenue	—no estimate	—no estimate	510,4M USD
Operating income	—no estimate	—no estimate	237,7M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution12 analysts

Strong buy5

Buy6

Hold1

Sell0

Strong sell0

12-month price target$364,53 · Median $386,50

Low $215,00High $474,00

Operating income · consensus237,7M USD

EPS surprise

−7,1 %

reported vs consensus · miss

Revenue surprise

−23,8 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$215,00

Mean$364,53

Median$386,50

High$474,00

Spot$312,57

+16.6 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin41,4 %Above P75

Net Margin52,6 %Above P75

ROE16,8 %Above median

Capex / Rev-3,1 %Below median

D/E0,00Above median

Cash Conv0,98Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 6 678 sh10 exercises · 7 grants5 insiders

ROMANO KATHRYNChief Accounting Officer · Restricted Stock Units → Common StockAcquired 5 442grant · 2026-02-27
ROMANO KATHRYNChief Accounting Officer · Performance Stock Units → Common StockDisposed 7 500exercise · 2026-02-27
ROMANO KATHRYNChief Accounting Officer · Restricted Stock Units → Common StockDisposed 550exercise · 2026-02-27
ROMANO KATHRYNChief Accounting Officer · Stock Option (Right to Buy) → Common StockAcquired 13 575 @ $275,64grant · 2026-02-27
Krishnan SumaDirector, President, R&D, 10% owner · Performance Stock Units → Common StockDisposed 22 500exercise · 2026-02-27
Krishnan SumaDirector, President, R&D, 10% owner · Restricted Stock Units → Common StockDisposed 4 000exercise · 2026-02-27
Krishnan SumaDirector, President, R&D, 10% owner · Stock Option (Right to Buy) → Common StockAcquired 18 100 @ $275,64grant · 2026-02-27
Krishnan SumaDirector, President, R&D, 10% owner · Restricted Stock Units → Common StockAcquired 7 256grant · 2026-02-27
Krishnan SumaDirector, President, R&D, 10% owner · Performance Stock Units → Common StockAcquired 43 536grant · 2026-02-27
Krishnan Krish SDirector, President and CEO, 10% owner · Restricted Stock Units → Common StockDisposed 8 750exercise · 2026-02-27
Krishnan Krish SDirector, President and CEO, 10% owner · Performance Stock Units → Common StockDisposed 26 250exercise · 2026-02-27
Krishnan Krish SDirector, President and CEO, 10% owner · Restricted Stock Units → Common StockDisposed 5 725exercise · 2026-02-27
Krishnan Krish SDirector, President and CEO, 10% owner · Stock Option (Right to Buy) → Common StockAcquired 45 249 @ $275,64grant · 2026-02-27
Krishnan Krish SDirector, President and CEO, 10% owner · Restricted Stock Units → Common StockAcquired 18 140grant · 2026-02-27
JANNEY DANIELDirector · Stock Option (Right to Buy) → Common StockDisposed 37 895 @ $2,46exercise · 2026-02-24
ROSSI DINO ADirector · Stock Option (Right to Buy) → Common StockDisposed 18 950 @ $8,79exercise · 2026-02-19
ROMANO KATHRYNChief Accounting Officer · Stock Option (Right to Buy) → Common StockDisposed 12 500 @ $63,55exercise · 2026-02-09

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Ev To Operating Cash Flow
enterprise_value / operating_cash_flow
Return On Equity
net_income / total_equity
Price To Earnings
market_price / (net_income / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)

Source documents

KRYS.O Market data — financials · 2026-05-28
Krystal Biotech Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

First Trust Advisors L.P.Investment Managers · as of 2026-03-310,06 %$91M
FMR LLCInstitutional Investor · as of 2026-03-310,06 %$1 130M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,03 %$69M
Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,03 %$213M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,03 %$121M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,02 %$42M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,02 %$725M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,01 %$0M
Nuveen LLCInvestment Managers · as of 2024-12-310,01 %$48M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,01 %$40M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,01 %$340M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,01 %$46M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,01 %$166M
Invesco QQQ TrustFunds · as of 2026-03-310,01 %$65M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,01 %$685M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$63M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$65M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$56M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,01 %$39M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,01 %$11M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$37M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$54M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$13M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$8M
Fisher InvestmentsInvestment Managers · as of 2026-03-310,00 %$7M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$4M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$4M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$3M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$1M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Net selling0 buys · 107 sellsnet -$78,7M6 insiders · last 365d

Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 11 461 @ $307,68$3,5M · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 320 @ $300,75$96K · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 593 @ $302,25$179K · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 247 @ $303,17$75K · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 400 @ $304,89$122K · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 480 @ $305,87$147K · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 1 348 @ $307,09$414K · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 12 729 @ $307,81$3,9M · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 3 803 @ $308,89$1,2M · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 2 801 @ $309,95$868K · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 2 039 @ $310,94$634K · 2026-06-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 240 @ $311,65$75K · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 320 @ $300,75$96K · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 640 @ $302,24$193K · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 176 @ $303,17$53K · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 544 @ $304,81$166K · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 589 @ $306,33$180K · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 4 830 @ $308,47$1,5M · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 2 784 @ $309,49$862K · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 2 652 @ $310,43$823K · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 964 @ $311,36$300K · 2026-06-04
Krishnan Krish SDirector, President and CEO, 10% owner · Common StockSold 40 @ $312,23$12K · 2026-06-04
Thomas John CharlesEVP, General Counsel · Common StockSold 642 @ $302,03$194K · 2026-05-26
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 668 @ $259,61$173K · 2026-03-04
Krishnan SumaDirector, President, R&D, 10% owner · Common StockSold 3 667 @ $260,37$955K · 2026-03-04

Short positioning

3.5Mshares short-0.6% vs prior

11.38days to cover

59.2%short of daily vol

5fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Held by funds 1

iShares Core S&P Small-Cap ETFBlackRock (iShares) · ETF0,53 %80,0B $ · #36

Funds (by AUM rank) that hold this security, with each fund's portfolio weight in this name.

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

KRYS.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob43 %Surprise-0,05Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Return on assets (FY 2025-12-31): 15.4%Derived (calculated)
Net margin (FY 2025-12-31): 52.6%Derived (calculated)
Return on equity (FY 2025-12-31): 16.8%Derived (calculated)
Current ratio (FY 2025-12-31): 9.95xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 0.09xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 182.0%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 43.9%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 126.9%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 128.0%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 129.7%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 62.7%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 145.3%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 8.3%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 33.9%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 28.9%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 26.3%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 4.4%Derived (calculated)
Cash & equivalents (annual): USD 496.3MSEC XBRL filing
Total liabilities (annual): USD 114.23MSEC XBRL filing
Operating income (annual): USD 161.29MSEC XBRL filing
Revenue (annual): USD 389.13MSEC XBRL filing
R&D expense (annual): USD 58.05MSEC XBRL filing
Capex (annual): USD 11.95MSEC XBRL filing
Total operating expenses (annual): USD 227.84MSEC XBRL filing

Showing 24 of 56 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-08-03EVENTQ2 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-04 00:00 UTCINSIDER22 insider transactions — 2026-06 · net sell $15.4M

2026-06-04INSIDERKrishnan Krish S sold 11.5k sh — Director, President and CEO, 10% owner ~$3.53M

2026-06-04INSIDERKrishnan Suma sold 320 sh — Director, President, R&D, 10% owner ~$96k

2026-06-04INSIDERKrishnan Suma sold 593 sh — Director, President, R&D, 10% owner ~$179k

2026-06-04INSIDERKrishnan Suma sold 247 sh — Director, President, R&D, 10% owner ~$75k

2026-06-04INSIDERKrishnan Suma sold 400 sh — Director, President, R&D, 10% owner ~$122k

2026-06-04INSIDERKrishnan Suma sold 480 sh — Director, President, R&D, 10% owner ~$147k

2026-06-04INSIDERKrishnan Suma sold 1.3k sh — Director, President, R&D, 10% owner ~$414k

2026-06-04INSIDERKrishnan Suma sold 12.7k sh — Director, President, R&D, 10% owner ~$3.92M

2026-06-04INSIDERKrishnan Suma sold 3.8k sh — Director, President, R&D, 10% owner ~$1.17M

2026-06-04INSIDERKrishnan Suma sold 2.8k sh — Director, President, R&D, 10% owner ~$868k

2026-06-04INSIDERKrishnan Suma sold 2.0k sh — Director, President, R&D, 10% owner ~$634k

2026-06-04INSIDERKrishnan Suma sold 240 sh — Director, President, R&D, 10% owner ~$75k

2026-06-04INSIDERKrishnan Krish S sold 320 sh — Director, President and CEO, 10% owner ~$96k

2026-06-04INSIDERKrishnan Krish S sold 640 sh — Director, President and CEO, 10% owner ~$193k

2026-06-04INSIDERKrishnan Krish S sold 176 sh — Director, President and CEO, 10% owner ~$53k

2026-06-04INSIDERKrishnan Krish S sold 544 sh — Director, President and CEO, 10% owner ~$166k

2026-06-04INSIDERKrishnan Krish S sold 589 sh — Director, President and CEO, 10% owner ~$180k

2026-06-04INSIDERKrishnan Krish S sold 4.8k sh — Director, President and CEO, 10% owner ~$1.49M

2026-06-04INSIDERKrishnan Krish S sold 2.8k sh — Director, President and CEO, 10% owner ~$862k

2026-06-04INSIDERKrishnan Krish S sold 2.7k sh — Director, President and CEO, 10% owner ~$823k

2026-06-04INSIDERKrishnan Krish S sold 964 sh — Director, President and CEO, 10% owner ~$300k

2026-06-04INSIDERKrishnan Krish S sold 40 sh — Director, President and CEO, 10% owner ~$12k

2026-05-26 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $194k

2026-05-26INSIDERThomas John Charles sold 642 sh — EVP, General Counsel ~$194k

2026-05-20FILING8-K filing →

2026-05-04FILING8-K filing →

2026-05-04FILING10-Q filing →

2026-04-03FILINGDEF 14A filing →

2026-03-04 00:00 UTCINSIDER21 insider transactions — 2026-03 · net sell $13.4M

2026-03-04INSIDERKrishnan Suma sold 668 sh — Director, President, R&D, 10% owner ~$173k

2026-03-04INSIDERKrishnan Suma sold 3.7k sh — Director, President, R&D, 10% owner ~$955k

2026-02-27 00:00 UTCINSIDER76 insider transactions — 2026-02 · net sell $44.5M 17 derivative

2026-02-27INSIDERROMANO KATHRYN acquired 5.4k sh Restricted Stock Units — Chief Accounting Officer

2026-02-27INSIDERROMANO KATHRYN disposed of 7.5k sh Performance Stock Units — Chief Accounting Officer

2026-02-27INSIDERROMANO KATHRYN disposed of 550 sh Restricted Stock Units — Chief Accounting Officer

Showing the 40 most recent of 63 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Held by funds 1

Geographic breakdown

Intel & risk

Evidence & claims

The Thread